Vrachimis Alexis, Schmid Kurt Werner, Jürgens Heribert, Schober Otmar, Weckesser Matthias, Riemann Burkhard
Department of Nuclear Medicine, University of Münster, Institute of Pathology and Neuropathology, University of Duisburg-Essen, Children's Hospital-Department for Pediatric Hematology and Oncology, University of Münster.
Dtsch Arztebl Int. 2013 Dec 13;110(50):861-6. doi: 10.3238/arztebl.2013.0861.
Brain metastases arise in roughly 0.9% of all cases of differentiated thyroid cancer. The median survival of adult patients with thyroid carcinoma that has metastasized to the brain is less than one year. Radioactive iodine treatment is only rarely given because its efficacy is not documented. In children, the situation may be different.
In 2005, a 15-year-old girl underwent thyroidectomy, and an oxyphilic variant of papillary thyroid carcinoma was found in ectopic thyroid tissue. The patient underwent oral, high-dose radioactive iodine treatment. The post-therapeutic I-131 whole-body scan revealed multiple metastases in the skeleton, lungs, and the soft tissues, along with physiological uptake of the residual thyroid tissue. Magnetic resonance imaging of the head revealed two brain metastases.
When the initial treatment was completed, additional age-adapted high-dose radioactive iodine treatment was given, up to a total activity level of 35 GBq. There followed a complete remission of all metastases in the brain, bones, lungs, and soft tissues. Computed tomography of the chest revealed stable residuals. Over the ensuing 7.5 years of follow-up, the thyroglobulin values steadily declined to less than 2 ng/mL. The patient was asymptomatic at her last follow-up in May 2013. She did not develop any delayed reaction to high-dose radioactive iodine treatment (in particular, she did not develop leukemia or any other secondary malignancy). She remained fertile: after completion of the treatment, she had two healthy children.
In this patient with multifocal thyroid carcinoma, a rare entity, radioactive iodine treatment was successful as the single treatment. This case illustrates the point that a given therapeutic modality might succeed in an individual case despite a total or near-total lack of efficacy for most patients in the same situation.
在所有分化型甲状腺癌病例中,脑转移的发生率约为0.9%。甲状腺癌已转移至脑的成年患者的中位生存期不到一年。放射性碘治疗很少使用,因为其疗效尚无文献记载。在儿童中,情况可能有所不同。
2005年,一名15岁女孩接受了甲状腺切除术,在异位甲状腺组织中发现了乳头状甲状腺癌的嗜酸性变体。患者接受了口服高剂量放射性碘治疗。治疗后的I-131全身扫描显示骨骼、肺部和软组织有多处转移,以及残留甲状腺组织的生理性摄取。头部磁共振成像显示有两处脑转移。
初始治疗完成后,给予了额外的适合年龄的高剂量放射性碘治疗,总活度达到35GBq。随后,脑、骨、肺和软组织中的所有转移灶完全缓解。胸部计算机断层扫描显示残留病灶稳定。在随后的7.5年随访中,甲状腺球蛋白值稳步下降至低于2ng/mL。在2013年5月的最后一次随访中,患者无症状。她没有出现高剂量放射性碘治疗的任何延迟反应(特别是,她没有患白血病或任何其他继发性恶性肿瘤)。她仍有生育能力:治疗完成后,她育有两个健康的孩子。
在这名患有多灶性甲状腺癌(一种罕见病症)的患者中,放射性碘治疗作为单一治疗方法取得了成功。该病例表明,尽管在相同情况下大多数患者完全或几乎完全没有疗效,但某种治疗方式在个别病例中可能会取得成功。